Work

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML

Year: 2018

Type: article

Abstract: Key Points PP2A inhibition occurs in AML by 2 different pathways: CIP2A in normal karyotype patients and SETBP1 in adverse karyotype patients. AKTS473 phosphorylation is a predictor of survival, and diagnostic levels of AKTS473 could be a novel biomarker in AML.

Source: Blood Advances

DOI: 10.1182/bloodadvances.2017013615

Authors: Claire M. Lucas, Laura J. Scott, Natasha Carmell, Alison K. Holcroft, Robert K. Hills, Alan K. Burnett, Richard E. Clark

Institutions: University of Liverpool, Royal Liverpool and Broadgreen University Hospital NHS Trust, Broadgreen Hospital, Cardiff University

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,800

Funder: Cancer Research UK

Awards: G7201224627, G8507756562

OpenAlex ID: W2802333688

FWCI: 1.823

Cites: 23

Cited by: 21

Related to: 10